Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007-2014.
Estimated ASCVD risk according to statin use in US adults with borderline triglycerides: Results from National Health and Nutrition Examination Survey (NHANES) 2007-2014.
复制标题
估计的ASCVD风险根据美国成年人患有边界甘油三酸酯的成年人的汀类药物的使用：国家健康和营养检查调查（NHANES）2007-2014的结果。
DOI：
10.1016/j.ajpc.2020.100087
复制
发表时间：
2020-09
影响因子：
4.1
通讯作者：
Nathan D W
中科院分区：
文献类型：
--
作者：
Fan W;Philip S;Toth PP;Granowitz C;Nathan D W
甘油三酯(TG)升高与动脉粥样硬化性心血管疾病(ASCVD)有关。尽管接受他汀类药物治疗，但许多美国成年人的甘油三酯水平接近或升高。他汀类药物使用者中与临界甘油三酯水平相关的ASCVD风险尚未确定，包括将持续ASCVD事件的成年人的估计数量。我们从2007-2014年的国家健康和营养检查调查中研究了4986名美国成年人(权重为1.13亿)，年龄在40-74岁之间。在服用他汀类药物的人中，低(5%)、临界(7.5%)、中等(7.5%)和高(≥20%)10年ASCVD风险的比例被量化为低(70%mg/dL，70-lt；100%mg/dL)，临界(100-lt；135mg/dL和135-lt；150mg/dL)，边缘高(150-lt；200(mg/dL)和升高(≥200(mg/dL)TG)。多元Logistic回归分析了这些TG类别与高危状态的关系。总体而言，18.6%的参与者TG为<；70mg/dL，24.2%TG 70-lt；100mg/dL，22.0%TG 100-lt；135mg/dL，6.2%TG 135-lt；150mg/dL，15.0%TG 150-mg/dL，14.0%TG≥-200mg/dL。这些组的10年平均ASCVD风险分别为5.6%、6.9%、7.8%、10.3%、9.6%和10.8%(p<<；>0.0001)。在他汀类药物使用者中，TGS超过135mg/dL的五分之一或更多的人处于≥20%的10年ASCVD风险，所有TG组中≥60%的人处于临界或更高的ASCVD风险。与Tgs<；70mg/dL组相比，多因素Logistic回归显示，尽管包括高密度脂蛋白胆固醇在内的因素调整，但在总体样本中，TG组Tg组与TgS<；70 mg/dL组相比，优势比为3.1~4.6(p<；0.05与p<；0.01)，而在TG组中，≥135mg/dL组的优势比为3.4至8.1(p<；0.05与p<；0.01)。尽管他汀类药物治疗，许多TGS水平达到临界值的美国成年人仍处于ASCVD风险升高的境地，这表明首先需要做出更大的生活方式改变努力，如果有迹象表明，循证治疗可以降低这种残留的ASCVD风险。
Elevated triglycerides (TGs) are associated with atherosclerotic cardiovascular disease (ASCVD). Despite statin therapy, many US adults have borderline or elevated TG levels. Not characterized is the ASCVD risk associated with borderline TG levels in statin users, including the estimated number of adults who will sustain ASCVD events. We studied 4986 US adults (weighted to 113 million) aged 40–74 from the National Health and Nutrition Examination Surveys 2007–2014. The proportion of persons at low (<5%), borderline (5-<7.5%), intermediate (7.5-<20%), and high (≥20%) 10-year ASCVD risk among those on statins was quantified for low (<70 mg/dL, 70-<100 mg/dL), borderline (100-<135 mg/dL and 135-<150 mg/dL), borderline high (150-<200 mg/dL), and elevated (≥200 mg/dL) TGs. Multiple logistic regression examined these TG categories in relation to high risk status. Overall, 18.6% of participants had TG < 70 mg/dL, 24.2% TG 70-<100 mg/dL, 22.0% TG 100-<135 mg/dL, 6.2% TG 135-<150 mg/dL, 15.0% TG 150-<200 mg/dL, and 14.0% TG ≥ 200 mg/dL. Mean 10-year ASCVD risk for these groups were 5.6%, 6.9%, 7.8%, 10.3%, 9.6% and 10.8%, respectively (p < 0.0001). One-fifth or more of statin users with TGs over 135 mg/dL were at ≥ 20% 10-year ASCVD risk and ≥60% of persons in all TG groups were at borderline or higher ASCVD risk. Compared to those with TGs <70 mg/dL, multiple logistic regression showed odds ratios of 3.1 to 4.6 (p < 0.05 to p < 0.01) for those in TG groups ≥135 mg/dL in the overall sample, but 3.4 to 8.1 (p < 0.05 to p < 0.01) for those in TG groups of ≥100 mg/dL in statin users, despite adjustment including HDL-C. Many US adults with borderline levels of TGs are at elevated ASCVD risk despite statin therapy, suggesting the need first for greater lifestyle modification efforts, and when indicated, evidence-based therapies known to reduce this residual ASCVD risk.
登录
查看更多内容
影响因子：
168.9
作者：
Sarwar, Nadeem;Sandhu, Manjinder S.;Ricketts, Sally L.;Butterworth, Adam S.;Di Angelantonio, Emanuele;Boelcholdt, S. Matthijs;Ouwehand, Willem;Watkins, Hugh;Samani, Nilesh J.;Saleheen, Danish;Lawlor, Debbie;Reilly, Muredach P.;Hingorani, Aroon D.;Talmud, Philippa J.;Danesh, John;Braund, P. S.;Hall, A. S.;Thompson, J.;Marz, W.;Sivapalaratnam, S.;Soranzo, N.;Trip, M.;Casas, J. P.;Ebrahim, S.;Arsenault, B. J.;Boekholdt, S. M.;Khaw, K. T.;Wareham, N. J.;Grallert, H.;Illig, T.;Humphries, S. E.;Rader, D. J.;He, J.;Clarke, R.;Hamsten, R.;Hopewell, J. C.;Frossard, P.;Deloukas, P.;Ye, S.;Simpson, J. A.;Onat, A.;Komurcu-Bayrak, E.;Martinelli, N.;Olivieri, O.;Girelli, D.;Kivimaki, M.;Kumari, M.;Aouizerat, B. E.;Baum, L.;Campos, H.;Chaaba, R.;Chen, B. S.;Cho, E. Y.;Evans, D.;Hill, J.;Hsu, L. A.;Hubacek, J. A.;Lai, C. Q.;Lee, J. H.;Klos, K.;Liu, H.;Masana, L.;Melegh, B.;Nabika, T.;Ribalta, J.;Ruiz-Narvaez, E.;Thomas, G. N.;Tomlinson, B.;Szalai, C.;Vaverkova, H.;Yamada, Y.;Yang, Y.;Tipping, R. W.;Ford, C. E.;Pressel, S. L.;Ballantyne, C.;Brautbar, A.;Knuiman, M.;Winchup, P. H.;Wannamethee, S. G.;Morris, R. W.;Kiechl, S.;Willeit, J.;Santer, P.;Mayr, A.;Wald, N.;Yarnell, J. W. G.;Gallacher, J.;Casiglia, E.;Tikhonoff, V.;Cushman, M.;Psaty, B. M.;Tracy, R. P.;Tybjaerg-Hansen, A.;Nordestgaard, B. G.;Benn, M.;Frikke-Schmidt, R.;Giampaoli, S.;Palmieri, L.;Panico, S.;Vanuzzo, D.;Pilotto, L.;Gomez de la Camara, A.;Gomez-Gerique, J. A.;Simons, L.;McCallum, J.;Friedlander, Y.;Fowkes, F. G. R.;Lee, A. J.;Taylor, J.;Guralnik, J. M.;Phillips, C. L.;Wallace, W. R.;Blazer, D. G.;Brenner, H.;Raum, E.;Mueller, H.;Rothenbacher, D.;Jansson, J. H.;Wennberg, P.;Nissinen, A.;Donfrancesco, C.;Salomaa, V.;Harald, K.;Pencina, M. J.;Vartiainen, E.;D'Agostino, R. B.;Vasan, R. S.;Bladbjerg, E. M.;Jorgensen, T.;Moller, L.;Jespersen, J.;Dankner, R.;Chetrit, A.;Lubin, F.;Bjoerkelund, C.;Lissner, L.;Bengtsson, C.;Cremer, P.;Nagel, D.;Rodriguez, B.;Dekker, J. M.;Nijpels, G.;Stehouwer, C. D. A.;Sato, S.;Iso, H.;Kitamura, A.;Noda, H.;Salonen, J. T.;Nyssoenen, K.;Tuimainen, T. -P.;Voutilainen, S.;Meade, T. W.;Cooper, J. A.;Kuller, L. H.;Grandits, G.;Gillum, R.;Mussolino, M.;Rimm, E.;Hankinson, S.;Manson, J. A. E.;Pai, J. K.;Bauer, K. A.;Naito, Y.;Amouyel, P.;Arveiler, D.;Evans, A.;Ferrieres, J.;Schulte, H.;Assmann, G.;Packard, C. J.;Sattar, N.;Westendorp, R. G.;Buckley, B. M.;Cantin, B.;Lamarche, B.;Despres, J. -P.;Dagenais, G. R.;Barrett-Connor, E.;Wingard, D. L.;Bettencourt, R.;Gudnason, V.;Aspelund, T.;Sigurdsson, G.;Thorsson, B.;Trevisan, M.;Tunstall-Pedoe, H.;Tavendale, R.;Lowe, G. D. O.;Woodward, M.;Howard, B. V.;Zhang, Y.;Best, L.;Umans, J.;Ben-Shlomo, Y.;Davey-Smith, G.;Njolstad, I.;Mathiesen, E. B.;Lochen, M. L.;Wilsgaard, T.;Ingelsson, E.;Lind, I.;Giedraitis, V.;Michaeelsson, K.;Brunner, E.;Shipley, M.;Ridker, P.;Buring, J.;Shepherd, J.;Cobbe, S. M.;Ford, I.;Robertson, M.;Marin Ibanez, A.;Feskens, E. J. M.;Kromhout, D.;Walker, M.;Watson, S.;Collins, R.;Kaptoge, S.;Perry, P. L.;Sarwar, N.;Thompson, A.;Thompson, S. G.;White, I. R.;Wood, A. M.
通讯作者：
Wood, A. M.
影响因子：
24
作者：
Grundy, Scott M.;Stone, Neil J.;Wijeysundera, Duminda N.
通讯作者：
Wijeysundera, Duminda N.
影响因子：
37.8
作者：
Miller, Michael;Stone, Neil J.;Pennathur, Subramanian
通讯作者：
Pennathur, Subramanian
DOI：
10.1097/00043798-199604000-00014
发表时间：
1996-04-01
期刊：
Journal of cardiovascular risk
影响因子：
--
作者：
Hokanson, J E;Austin, M A
通讯作者：
Austin, M A
影响因子：
3.5
作者：
Onat, A;Sari, I;Avci, GS
通讯作者：
Avci, GS